about
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.Cluster analysis of immunophenotypic data: the example of chronic lymphocytic leukemia.Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cellsDetection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study.The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells.Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.Stathmin activity influences sarcoma cell shape, motility, and metastatic potential.BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stressIntrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance.CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells.B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage.Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy.Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.Functional and Clinical Significance of the Integrin Alpha Chain CD49d Expression in Chronic Lymphocytic Leukemia.Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia.The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells.CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanismsSurface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance.CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance.CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemiaMutational status of IgV(H) genes in B-cell chronic lymphocytic leukemia and prognosis: percent mutations or antigen-driven selection?Clinical significance of c.7544-7545 delCT NOTCH1 mutation in chronic lymphocytic leukaemia.CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival.Ibrutinib Inhibits VLA-4-Dependent Adhesion in CLL-Letter.Mutational status of IGHV is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia.Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling.CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells.Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome.Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery.PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.NOTCH1 mutations are associated with high CD49d expression in chronic lymphocytic leukemia: link between the NOTCH1 and the NF-κB pathways.NOTCH1 mutational status in chronic lymphocytic leukaemia: clinical relevance of subclonal mutations and mutation types.Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia.NOTCH1-mutated chronic lymphocytic leukemia cells are characterized by a MYC-related overexpression of nucleophosmin 1 and ribosome-associated components.Laminin-332 (Laminin-5) is the major motility ligand for B cell chronic lymphocytic leukemia.Persistent CD49d engagement in circulating CLL cells: a role for blood-borne ligands?
P50
Q30657004-F2CCD106-4585-4FD6-BB7A-2C90106CE7B8Q33711084-AF5BF507-3B48-42D8-BB83-D3FAAF944B53Q33758834-ADACE865-E98E-45D3-9379-B2D45AB45D26Q34461989-05DFFF63-AD2E-4A72-A051-3D7835BBCCD9Q35717883-C8022926-6907-492F-A7E1-0D51E75A4809Q36326340-0575D23A-B2F3-44C2-B721-66166679527AQ36420752-C85AF185-F14A-4B93-9A86-01A869E35C95Q36631230-7E1537DD-F3FF-4CED-A0A0-48FEFBF2C34AQ37330894-5E50C49C-CDE9-4F54-9FDB-39A49FC14D31Q37588785-553898D0-D8EE-427F-AB79-0C6A176E9FD4Q37785316-F8239CB5-D9F8-4553-9B30-8A2D24CCD689Q37837955-60CAF042-D064-4572-B5B4-5ED18AEC3868Q38010501-8D068D87-75A3-4424-AEB1-3B208A9FE1FCQ38232480-1EAF61D2-72EF-4016-9B06-5741473BD7D6Q38925105-8BD4357C-6FE8-49E7-9C6E-C4BA607FF647Q38945688-F206E3E7-65F8-43A3-9C0A-410DD3986C26Q39404177-CBFE371E-AAA5-446E-A828-E8EC80D9F130Q39865621-9F6FD961-4D6C-478F-A402-AA7DD7B8E177Q40366836-6749F242-23E8-4B7C-BEE2-8D1473065D9EQ40784167-258AE2E4-4658-4386-8D4F-9246E6755468Q42702972-DCD3B6E4-0528-4B8A-B9C7-CD7F580FACEAQ42770092-B55250C9-5E8A-4C41-9955-43B7633E70CFQ43518448-C60B4ED5-F39E-4CD3-AAAF-8E5A4BEF4AC3Q43558209-A097E1BE-4DBA-48ED-A101-BC98121E2BFFQ44276636-E7C52416-8020-461B-A52A-528E168F6061Q44558291-DF10941B-1C3E-42D2-8095-B2E0DDAE54AFQ44752987-3F2D6CA7-2D29-47E0-8BFA-89F1735F1195Q45191343-A9A54181-03B1-4BB6-A4FB-E26BF725EDFEQ46467811-AD79ACBC-A232-4348-B6F1-E4F3BF9303D1Q46585922-9A8E94B4-7B35-44B9-AFF7-931DB634799AQ47339225-F0E42494-ED7C-4A2F-A1BA-687761FB0D8AQ47608454-A134F4C1-05BB-4D7B-9389-14636B202C72Q47945189-0676E4E9-2931-4923-BF5C-4E8F12471F99Q48140340-9AF06135-A813-4E03-9A6F-0F84E78AE218Q48307279-11F9F7A5-1381-4C51-99E6-3DEC7AB3827BQ48958626-69251F6D-0190-4D6B-B73D-5284EA5FF3E3Q51025698-5F181B6C-2437-4317-B2A6-06A828D7E5A4Q51093052-F9C07B9F-A55A-4478-A145-42D9D7E5765DQ52578912-67096CF6-45B5-4E5C-A3BA-E8EF43433F1DQ52930409-EA379556-FDC0-4312-9C32-D2800DADC0EA
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonella Zucchetto
@ast
Antonella Zucchetto
@en
Antonella Zucchetto
@es
Antonella Zucchetto
@nl
type
label
Antonella Zucchetto
@ast
Antonella Zucchetto
@en
Antonella Zucchetto
@es
Antonella Zucchetto
@nl
prefLabel
Antonella Zucchetto
@ast
Antonella Zucchetto
@en
Antonella Zucchetto
@es
Antonella Zucchetto
@nl
P1053
J-6541-2016
P106
P1153
55312443400
P21
P31
P3829
P496
0000-0003-3678-5957